Diagnostic delay in Crohn's disease is associated with a complicated disease course and increased operation rate

American Journal of Gastroenterology

Volumn 108, Issue 11, 2013, Pages 1744-1753

  Schoepfer, Alain M ^a   Dehlavi, Mohamed Ali ^a   Fournier, Nicolas ^b   Safroneeva, Ekaterina ^c   Straumann, Alex ^d   Pittet, Valérie ^b   Peyrin Biroulet, Laurent ^e   Michetti, Pierre ^a,f   Rogler, Gerhard ^g   Vavricka, Stephan R ^g,h  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e UNIVERSITÉ DE LORRAINE   (France)

^f Clinique La Source   (Switzerland)

^g UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^h Division of Gastroenterology and Hepatology   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE;

ADULT; ANUS FISTULA; ARTICLE; CROHN DISEASE; DELAYED DIAGNOSIS; DISEASE COURSE; DISEASE DURATION; DRUG USE; FEMALE; FOLLOW UP; HUMAN; INTESTINE STENOSIS; INTESTINE SURGERY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PRIVATE PRACTICE; UNIVERSITY HOSPITAL;

ADULT; CONSTRICTION, PATHOLOGIC; CROHN DISEASE; DELAYED DIAGNOSIS; DISEASE PROGRESSION; FEMALE; HUMANS; INTESTINAL DISEASES; MALE; MIDDLE AGED; RISK FACTORS;

EID: 84887257693     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2013.248     Document Type: Article

References (30)

1. Perminow G, Brackmann S, Lyckander LG et al. A characterization in childhood infl ammatory bowel disease, a new population-based inception cohort from South-Eastern Norway, 2005-07, showing increased incidence in Crohn's disease. Scand J Gastroenterol 2009; 44: 446-56.
2. Perminow G, Frigessi A, Rydning A et al. Incidence and clinical presentation of IBD in children: comparison between prospective and retrospective data in a selected Norwegian population. Scand J Gastroenterol 2006; 41: 1433-9. (Pubitemid 44764404)
3. Loft us CG, Loft us EV Jr, Harmsen WS et al. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Infl amm Bowel Dis 2007; 13: 254-61.
4. Pimentel M, Chang M, Chow WJ et al. Identifi cation of a prodromal period in Crohn's disease but not ulcerative colitis. Am J Gastroenterol 2000; 95: 3458-62.
5. Talley NJ, Phillips SM, Melton LJ et al. Diagnostic value of the Manning criteria in irritable bowel syndrome. Gut 1990; 31: 77-81. (Pubitemid 20037984)
6. Hammer J, Talley NJ. Value of different diagnostic criteria for the irritable bowel syndrome among men and women. J Clin Gastroenterol 2008; 42: 160-6.
7. Vavricka SR, Spigaglia SM, Rogler G et al. Systematic evaluation of risk factors for diagnostic delay in infl ammatory bowel disease. Infl amm Bowel Dis 2012; 18: 496-505.
8. Punati J, Markowitz J, Lerer T et al. Effect of early immunomodulator use in moderate to severe pediatric Crohn's disease. Infl amm Bowel Dis 2008; 14: 949-54.
9. Markowitz J. Early infl ammatory bowel disease: different treatment response to specifi c or all medications? Dig Dis 2009; 27: 358-65.
10. Etchevers MJ, Aceituno M, Sans M. Are we giving azathioprine too late? The case for early immunomodulation in infl ammatory bowel disease. World J Gastroenterol 2008; 14: 5512-8.
11. Ricart E, Garcia-Bosch O, Ordas I et al. Are we giving biologics too late? The case for early versus late use. World J Gastroenterol 2008; 14: 5523-7.
12. Gupta N, Bostrom AG, Kirschner BS et al. Presentation and disease course in early compared to later-onset pediatric Crohn's disease. Am J Gastroenterol 2008; 103: 2092-8.
13. Pittet V, Juillerat P, Mottet C et al. Cohort profi le: the Swiss Infl ammatory Bowel Disease Cohort Study (SIBDCS). Int J Epidemiol 2009; 38: 922-31.
14. Silverberg MS, Satsangi J, Ahmad T et al. Toward an integrated clinical, molecular and serological classifi cation of infl ammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 19 (Suppl A): 5-36.
15. Cosnes J, Cattan S, Blain A et al. Long-term evolution of disease behavior of Crohn's disease. Infl amm Bowel Dis 2002; 8: 244-50. (Pubitemid 34784976)
16. Louis E, Collard A, Oger AF et al. Behaviour of Crohn's disease according to the Vienna classifi cation: changing pattern over the course of the disease. Gut 2001; 49: 777-82. (Pubitemid 33096034)
17. Cosnes J, Nion-Larmurier I, Beaugerie L et al. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005; 54: 237-41. (Pubitemid 40139240)
18. Munkholm P, Langholz E, Davidsen M et al. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 1995; 30: 699-706.
19. Solberg IC, Vatn MH, Hoie O et al. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol 2007; 5: 1430-8. (Pubitemid 350181602)
20. Mekhjian HS, Switz DM, Melnyk CS et al. Clinical features and natural history of Crohn's disease. Gastroenterology 1979; 77: 898-906. (Pubitemid 9257853)
21. Wolters FL, Russel MG, Stockbrugger RW. Systematic review: has disease outcome in Crohn's disease changed during the last four decades? Aliment Pharmacol Ther 2004; 20: 483-96. (Pubitemid 39243894)
22. Picco MF, Zubiaurre I, Adluni M et al. Immunomodulators are associated with a lower risk of fi rst surgery among patients with non-penetrating non-stricturing Crohn's disease. Am J Gastroenterol 2009; 104: 2754-9.
23. Lichtenstein GR. Infl iximab: lifetime use for maintenance is appropriate in Crohn's disease. PRO: maintenance therapy is superior to episodic therapy. Am J Gastroenterol 2005; 100: 1433-5. (Pubitemid 41032341)
24. Feagan BG, Panaccione R, Sandborn WJ et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology 2008; 135: 1493-9.
25. Lemann M, Mary JY, Colombel JF et al. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology 2005; 128: 1812-8. (Pubitemid 40824692)
26. Peyrin-Biroulet L, Loft us EV Jr, Colombel JF et al. Early Crohn's disease: a proposed defi nition for use in disease-modifi cation trials. Gut 2010; 59: 141-7.
27. Spencer DM, Veldman GM, Banerjee S et al. Distinct infl ammatory mechanisms mediate early versus late colitis in mice. Gastroenterology 2002; 122: 94-105. (Pubitemid 34049199)
28. Schoepfer AM, Trummler M, Seeholzer P et al. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Infl amm Bowel Dis 2008; 14: 32-9. (Pubitemid 351196866)
29. Van Rheenen PF, Van der Vijer E, Fidler V. Faecal calprotectin for screening of patients with suspected infl ammatory bowel disease: diagnostic metaanalysis. BMJ 2010; 341: c3369. Review.
30. Keohane J, O ' Mahony C, O ' Mahony L et al. Irritable bowel syndrome-type symptoms in patients with infl ammatory bowel disease: a real association or refl ection of occult infl ammation? Am J Gastroenterol 2010; 105: 1789-94.